-

VectorY Announces Participation in Scientific Conferences in October 2022

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neuro-degenerative and muscular disorders through vectorized antibodies, today announces participation in three upcoming conferences.

5th Annual ALS Research Symposium (ALS ONE), 6-7 & 11 October, virtually

  • Presentation title: Reduction of oxidized phospholipids or misfolded protein aggregates by AAV-VecTabs in an Amyotrophic Lateral Sclerosis pre-clinical models
    Presenter: Pavlina Konstantinova, Chief Scientific Officer
    Time and date: October 7, 14:05 ET

European Society of Gene & Cell Therapy (ESGCT) Annual Congress, 11-14 October, Edinburgh

  • Poster title: VecTrons: Targeting misfolded proteins in neurodegenerative diseases
    Presenter: Menno Spits, Scientist
    Poster number: P251
    Time and date: October 12, Poster Session 1,19:30-21:00 BST
  • Poster title: Generation and characterization of stable recombinant baculoviruses for large-scale production of rAAV
    Presenter: Hilde van Tongeren, Head of Vector Generation
    Poster number: P293
    Time and date: October 12, Poster Session 1, 19:30-21:00 BST
  • Poster title: VecTabs® and advanced human in-vitro models: targeting TDP-43 aggregates and oxidized phosphocholines in Amyotrophic lateral sclerosis
    Presenter: Andreia Duarte, Scientist
    Poster number: P353
    Time and date: October 12, Poster Session 1, 19:30-21:00 BST
  • Poster title: Next generation rAAV capsids show enhanced transduction efficiency in 2D and 3D human cellular models for neurodegenerative diseases
    Presenter: Carmen Gallego, Scientist, Vector Technologies
    Poster number: P056
    Time and date: October 13, Poster Session 2, 17:30-19:15 BST

2022 Cell & Gene Meeting on the Mesa, 11-13 October, Carlsbad, CA

  • Presentation title: Precision targeted gene therapies for CNS and neuromuscular disease
    Presenter: Barbara Sanders, Chief Technology Officer
    Time and date: October 13, 11:45 PT

To meet the VectorY team at any of these meetings, please contact info@vectorytx.com.

ENDS

Notes to Editors

About VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and muscular diseases with high unmet medical need such as amyotrophic lateral sclerosis (ALS) and Huntington’s disease.

VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative and muscular diseases, VectorY's synergistic technologies may be applied across a wide range of indications.

VectoryY was founded in October 2020 and is based on the Amsterdam Science Park.

For more information, see www.vectorytx.com.

Contacts

VectorY B.V.
Sariette Witte, Head of Communications
Email: sariette.witte@vectorytx.com
Tel: +31 (20) 226 8020

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell /Giulia Lasagni/ Manisha Kuttetira
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020

Industry:

VectorY Therapeutics

Release Versions
English

Contacts

VectorY B.V.
Sariette Witte, Head of Communications
Email: sariette.witte@vectorytx.com
Tel: +31 (20) 226 8020

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell /Giulia Lasagni/ Manisha Kuttetira
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020

More News From VectorY Therapeutics

VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS)

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been dosed in its Phase 1/2 PIONEER-ALS trial evaluating VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in people with amyotrophic lateral sclerosis (ALS). The participant was treated at the lead clinical trial site, the Sean M. Healey & AMG Center for ALS at Mass General Brigham, a premi...

VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectoryY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today the appointment of Kevin Pojasek, Ph.D., to its Board of Directors. Dr. Pojasek brings more than two decades of expertise founding, scaling, and leading innovative biopharma companies, with deep expertise across corporate strategy, business development, and research and development. Dr. Pojasek is currently president and chief executive officer of...

VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS). “ALS is a devastating and relentlessly progressive disease with profound unmet medical need, and patients urgently need new therapeutic options,” sai...
Back to Newsroom